Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade - 29/04/13
Doi : 10.1016/j.jaci.2012.12.1520
Matthias Mehling, MD a, b, Volker Brinkmann, PhD c, Anne-Valerie Burgener, BMSc a, Patrick Gubser, MD a, Andrew D. Luster, MD, PhD d, Ludwig Kappos, MD b, 
, Christoph Hess, MD, PhD a, 
, Christoph Hess, MD, PhD a, a Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, University Hospital Basel, Basel, Switzerland
b Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine, University Hospital Basel, Basel, Switzerland
c Department of Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland
d Massachusetts General Hospital, Harvard Medical School, Center for Immunology and Inflammatory Diseases, Charlestown, Mass
| Supported by a grant from Novartis AG, Basel, Switzerland, and by the Swiss Multiple Sclerosis Society. C.H. and P.G. are supported by grants from the Swiss National Science Foundation (31003A_135677/1 and PB323630-128881, respectively). |
|
| Disclosure of potential conflict of interest: M. Mehling has received research support from the Novartis Research Foundation and the Swiss MS Society and is employed by University Hospital Basel. V. Brinkmann is employed by Novartis. L. Kappos has received research support from the Novartis Research Foundation (Basel, Switzerland), Bayer, Biogen Idec, Merck Serono, Novartis, Teva, Roche, the Swiss MS Society, the European Union, the Gianni Rubatto Foundation, the Roche Research Foundation, and the Novartis Research Foundation; is a member of the Actelion Data and Safety Monitoring Committee; is on the advisory boards for Advancell, Allozyne, and Wyeth; is chair of the Bayer, Novartis, and Roche Steering Committees; is member and chair of the Biogen Idec advisory board; is chair of the Genmab, MediciNova, Santhera, and UCB Data and Safety Monitoring Committee; is chair of the Merck Serono advisory board; is a member of the Merck Serono Steering Committee; is a member of the Teva advisory board and Steering Committee; has received consultancy fees from Novonordisk, Peptimmune, Glenmark, BioMarin, GeNeuro SA, Eli Lilly, CSL Behring, Bayhill, and Sanofi Aventis; has received lecture fees from Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, Roche, and Teva; and has received payment for the development of educational presentations from Bayer, Merck Serono, Novartis, Sanofi Aventis, Roche, Teva, and UCB. C. Hess has received research support from the Swiss National Science Foundation and Research Hub Basel University-Roche and is employed by University Hospital Basel. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2012
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 131 - N° 5
P. 1440 - mai 2013 Retour au numéro
Article précédent
- Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin κ-deleting recombination excision circles
- Chikako Kamae, Noriko Nakagawa, Hiroki Sato, Kenichi Honma, Noriko Mitsuiki, Osamu Ohara, Hirokazu Kanegane, Srdjan Pasic, Qiang Pan-Hammarström, Menno C. van Zelm, Tomohiro Morio, Kohsuke Imai, Shigeaki Nonoyama
- Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: A possible mechanism for therapeutic modulation of T cells
- Jorg van Loosdregt, Roberto Spreafico, Maura Rossetti, Berent J. Prakken, Martin Lotz, Salvatore Albani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?